Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Autolus Therapeutics (AUTL) Share-based Compensation (IS): 2017-2021

Historic Share-based Compensation (IS) for Autolus Therapeutics (AUTL) over the last 5 years, with Dec 2021 value amounting to $10.7 million.

  • Autolus Therapeutics' Share-based Compensation (IS) was N/A to $7,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $95.2 million, marking a year-over-year change of. This contributed to the annual value of $10.7 million for FY2021, which is 44.77% down from last year.
  • As of FY2021, Autolus Therapeutics' Share-based Compensation (IS) stood at $10.7 million, which was down 44.77% from $19.4 million recorded in FY2020.
  • In the past 5 years, Autolus Therapeutics' Share-based Compensation (IS) registered a high of $33.3 million during FY2019, and its lowest value of $2.5 million during FY2017.
  • Over the past 3 years, Autolus Therapeutics' median Share-based Compensation (IS) value was $19.4 million (recorded in 2020), while the average stood at $21.1 million.
  • In the last 5 years, Autolus Therapeutics' Share-based Compensation (IS) soared by 396.20% in 2019 and then tumbled by 44.77% in 2021.
  • Autolus Therapeutics' Share-based Compensation (IS) (Yearly) stood at $3.2 million in 2017, then reached $2.5 million in 2017, then surged by 35.52% to $4.3 million in 2018, then surged by 169.84% to $6.7 million in 2018, then spiked by 396.20% to $33.3 million in 2019, then plummeted by 41.89% to $19.4 million in 2020, then plummeted by 44.77% to $10.7 million in 2021.